After a late-stage failure, Chimerix is closing down two other late-stage trials and reassessing the path forward for its lead compound. Yet, management struck a positive tone on a conference call with analysts, indicating other formulations and better physician education could remedy the issues.
Chimerix stock tanked in late December when the company announced that its lead compound brincidofovir failed to meet its primary...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
